๐Ÿซ Chapter 456 ยท Diffuse Lung Diseases in Childhood

Nelson Textbook of Pediatrics 22nd Edition | Surfactant dysfunction disorders: SFTPB (lethal without transplant), SFTPC (variable, gain-of-function), ABCA3 (variable), NKX2-1 (brain-thyroid-lung syndrome). Pulmonary alveolar proteinosis (PAP): autoimmune (anti-GM-CSF antibodies) or genetic (CSF2RA/B mutations). Clinical: neonatal respiratory distress, chronic tachypnea, hypoxemia, failure to thrive. Diagnosis: HRCT (ground-glass, crazy-paving), genetic testing, lung biopsy (alveolar proteinosis, lamellar body abnormalities). Treatment: supportive, hydroxychloroquine (surfactant disorders), whole lung lavage (PAP), inhaled GM-CSF (autoimmune PAP), lung transplantation.

๐ŸŒ paeds.online โ€” Pakistan's Pediatric Platform

๐Ÿ“‹ 30 Clinical Scenarios โ€” Surfactant Dysfunction & PAP

๐Ÿ“‡ Highโ€‘Yield Cards: Diffuse Lung Diseases (Chap 456)

๐Ÿฉบ Interactive Clinical Approach: Diffuse Lung Disease in Children

Select a presentation for diagnostic and management approach.

๐Ÿ“‹ Stepwise Management of Surfactant Dysfunction & PAP

    DiseaseKey Genetic FindingsTreatment
    SFTPB deficiencyAutosomal recessive, frameshift mutation (121ins2)Lung transplantation (lethal without transplant)
    SFTPC deficiencyAutosomal dominant, gain-of-function (I73T common)Hydroxychloroquine, azithromycin, supportive, lung transplant if progressive
    ABCA3 deficiencyAutosomal recessive, variable severityHydroxychloroquine, supportive, lung transplant for severe
    NKX2-1 (brain-thyroid-lung)Hypothyroidism, chorea, lung diseaseThyroid hormone replacement, supportive, hydroxychloroquine for lung
    PAP (autoimmune)Anti-GM-CSF antibodiesWhole lung lavage, inhaled GM-CSF
    PAP (genetic)CSF2RA, CSF2RB mutations (GM-CSF receptor)Whole lung lavage, hematopoietic stem cell transplant

    โšก Reflex Prompts โ€” Diffuse Lung Disease Recognition

    ๐Ÿ“– Summary: Diffuse Lung Diseases โ€” Nelson 22nd Ed